![Ran Weinstock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ran Weinstock
Profile
Ran Weinstock served as an Independent Director at Bioblast Pharma Ltd.
He completed his undergraduate degree at Tel-Aviv University and his graduate degree at Bar-Ilan University and Netanya Academic College.
Former positions of Ran Weinstock
Companies | Position | End |
---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Director/Board Member | - |
Training of Ran Weinstock
Tel-Aviv University | Undergraduate Degree |
Netanya Academic College | Graduate Degree |
Bar-Ilan University | Graduate Degree |
Experiences
Positions held
Linked companies
Private companies | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Stock Market
- Insiders
- Ran Weinstock